In CLL cells, idelalisib abrogates the protective effect of many microenvironmental signals including CD40L, BAFF, TNFα, ET1, fibronectin adhesion as well as contact with stromal cells and NLC [38–40] (Fig. 1). The gene discussed is TNFSF13B; the disease is B-cell chronic lymphocytic leukemia.